Overview

Efficacy/Safety of Rosuvastatin+Ezetimibe in High Risk Patients With Primary Hypercholesterolemia/Mixed Dyslipidemia

Status:
Completed
Trial end date:
2014-11-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine the non-inferiority between two different FDC (fixed-dose combination), measuring LDL-Cholesterol levels, in high risk patients with primary hypercholesterolemia or mixed dyslipidemia.
Phase:
Phase 3
Details
Lead Sponsor:
Ache Laboratorios Farmaceuticos S.A.
Treatments:
Ezetimibe
Rosuvastatin Calcium
Simvastatin